Nov. 12, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 12 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) is the keynote presenting company at the founders’ celebration of consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The celebration will be attended by over 200 founders and guests of Regeneca International from across the United States. It will be hosted at the prestigious Balboa Bay Club in Newport Beach, California. Vivakor’s Chairman, Matt Nicosia and CFO, Ed Corrente will both be attending the event.

Event attendee, Dr. Brian Scott , a Regeneca advisory board member and nationally recognized wellness expert, was particularly pleased to learn of Vivakor’s role in the event. “As a healthcare provider and speaker on issues regarding wellness and longevity, it is refreshing to hear the perspective of a company, doing business internationally, which can provide a particular focus on products which extend the length and quality of a person’s life.”

The purpose of the event is to introduce Regeneca’s new product offerings that are to be released in the coming months, most significantly, the new nutraceutical formulation developed by Vivakor.”

About Vivakor, Inc.

Vivakor, Inc. is a transdisciplinary research company that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds. Vivakor also provides contract research services for third parties.

Vivakor’s business model is to be a research hub focused on areas that have both an identified scientific need and a substantial market opportunity with a significant market. This approach is intended to provide the necessary environment of transdisciplinary collaboration and cross-pollination to advance research and technology acquisition. Vivakor’s mission is to advance or acquire distinct intellectual property and technologies that improve the quality of life for individual patients, researchers, clinicians and consumers. Vivakor believes that the development and commercialization of substantive technologies and cures for complex human conditions, illnesses and diseases require a sophisticated approach with contribution from many areas of business and scientific expertise. Vivakor’s research and the technology it acquires are anchored by its relationship with collaborative partners and product-specific commercialization strategies. From the commencement of product conception or acquisition, through development and commercialization, the Company expects to have collaborative partners or licensing arrangements in place for each of its products. Vivakor expects this model to provide several advantages, including: (i) a more efficient research and development process; (ii) a quicker time to market after completion of development; and (iii) the value-add growth to the hub company, Vivakor, through commercialization and subsidiary spin-off.

Vivakor has commenced developing numerous products and currently has one pending utility patent. In October, 2008, it acquired a patented MRI software technology that it intends to develop. Vivakor generally intends to commercialize its products, after completion of development and any required regulatory approvals, primarily through one of three methods: (i) a sale of the technology; (ii) licensing of the product to a manufacturer or distributor or; (iii) by directly manufacturing, marketing and selling the products.

Product Research Divisions

Vivakor’s research efforts are divided into four primary areas of medical and biotechnological development. These are:

1. Molecular Medicine. The goal of this division centers on the development of biologically relevant molecules, tests and methods and their application in the practice of medicine.

Vivakor plans to translate systems biology (genomics, proteomics, metabalomics, etc.) insights of the molecular and cellular basis of disease into commercializable theranostic (diagnostic/therapeutic) products. Vivakor scientists will be participants in the discovery and development of new drugs and the early diagnosis of disease states.

The central aim of the molecular medicine division is cancer detection and wound healing, which we anticipate will lead to the development of customized treatments. Research in stem cell biology and nuclear reprogramming is a critical element in this research.

2. Electro-Optics. This division is charged with the development of biomedical and related consumer products that incorporate optical and electronic engineering. Vivakor has actively designed, built and tested several new electro-optic devices to reach previously un-served or underserved areas of the biomedical device market and believes the market potential during the first 12 months of commercialization of these products is over $15 million. Products scheduled for development in this area include:

• VivaSight: a digital photorefractor that is intended to modernize child vision screening. Approval has been granted from Western Institutional Review Board (20080731) to conduct human validation studies of the VivaSight technology on children. This study is currently being conducted at The University of Iowa Hospitals and Clinics.
• Clinical Biomolecular Sensor (CBS): a label free multiplexed approachfor use in the detection and diagnosis of complex human conditions (cancer, infectious diseases, cardiovascular disease, metabolic disorders, auto immune and inflammatory diseases)Multi-spectral Imaging: devices to examine burn degree and cutaneous melanoma and
• Spectroscopic devices: to track wound healing and ear infection.

With the acquisition of HealthAmerica’s SLICES(TM) technology, the Company plans to adapt and upgrade this technology to produce enhanced MRI images, which are expected to improve MRI resolution while providing additional data such as blood flow velocity in imaged tissues. The Company believes its potential market share for this product is over $300 million annually .

3. Biological Handling. Vivakor has developed commercial products for cryogengenic preservation, and storage through its VivaThermic Cryovials (USPTO Utility Patent # 12423998) which are currently being sold and have improved temperature control and were designed to improve cryopreservation and thawing of sensitive biological material. Vivakor expects that the market potential for its products is over $10 million over the next 12 months. It plans to continue to explore new techniques to improve methods and products employed for cryogenic preservation, storage and handling. Future research plans for this division include:

• stem cell specific improved cryovials;
• cryogenic devices for temperature maintenance and sample transport);
• a cryogenic biopsy device (Cryopsy); and
• improved modular cryogenic freezer designs.

4. Natural and Formulary Products. This division plans to focus on the investigation, validation and adaptation of medical herbalism or botanical medicine. The Company has already developed a series of nutraceutical formulations, including VivaBlend, and plan to develop additional nutraceuticals, botanicals and supplements. Vivakor recently received a 25,000 unit purchase order for one of our products from Regeneca, International. Future products for this division include:

• fruit and vegetable extract for the protection of digestive system
• fresh fruit and vegetable extract for antioxidant supplements; and
• jam and jelly formula to contain both antioxidant supplements as well as bone & cartilage supplements for healthy joints

More information can be found about Vivakor at www.vivakor.com.

About Regeneca International, Inc.

Regeneca(TM) International, Inc. was formed to create and commercialize products that help consumers improve their health, battle the signs and symptoms of aging and to assist you “regenerate their life” through its family of natural, organic and phytochemical infused products. The corporate creed is to regenerate the human genetic environment through ecology centric science. All REGENECA(TM) products must fit the highest standard of conservation, and reduced carbon footprint. The products must also work to preserve and promote the user’s health at the most elemental level of life; the genetic level. The Company’s products and philosophy are designed to reconnect the consumer to the Earth’s source of healing properties, but with a symbiotic approach. This is the Company’s “Whole Earth, Whole Body Approach to Health.”

Already a market presence in the multibillion dollar nutraceutical market, Regeneca’s proprietary, direct to consumer; marketing strategy has pushed the company to the forefront of emerging consumer product companies. Regeneca anticipates at least a 500% increase in sales in 2010 and a similar increase in 2011.

More information can be found about Regeneca International, Inc. at www.regeneca.com .

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor’s products and divisions and their related market potential. There may also be similar statements regarding Regeneca and its product divisions. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

Contact:
Vivakor, Inc.
Matt Nicosia, 319-625-2172
mnicosia@vivakor.com

Related posts

• Vivakor Launches Sales of VivaThermic Products to Exploding Biotech Sector in India (0)
• Vivakor Announces Former General Electric Healthcare Division Executive Joins Its Board of Directors (0)
• Vivakor Announces Distribution & Purchase Order Contract with Regeneca International, Inc. For Cutting-Edge Nutraceutical Formulation (0)
• Vivakor Announces Completion of Pilot Product Evaluation of Nutraceutical Product with Consumer Product Specialist, Regeneca International, Inc. (0)
• 9-30-09 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com (1)

Last 5 posts by Stuart T. Smith

• Solutions Group Inc. Announces Partnership With ARI Insurance - December 2nd, 2009
• 12-2-09 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com - December 2nd, 2009
• Solutions Group Announces Participation in Nation Wide Teen Driver Study - December 2nd, 2009
• A New Audio Interview with Douglas B. Thomas, President CEO of Rival Technologies Inc., is Now at SmallCapVoice.com - December 2nd, 2009
• Mariner’s Choice (MCII) Delivers First Shipment to the Caribbean - December 2nd, 2009